应用克隆培养方法,以及Ara-C,6-TG,MTX,VCR,Adr,HHT六种药物。对51例初治急非淋白血病(ANLL)病人细胞进行体外药敏试验,20例同时有体内治疗结果资料。体内外结果比较表明,病人使用的治疗药物体外敏感,临床72.7%缓解,其中4例同时有二种治疗药物体外敏感,临床均获得缓解;只有一种治疗药物体外敏感。7例中4例缓解。9例病人所有治疗药物体外试验均不敏感,8例不缓解。因此本组病人体外药敏测定能够联系临床结果,并提示如体外选择一或一种以上敏感药物治疗,有可能显著提高白血病人的治疗缓解率。 Application of cloning and culture methods, and Ara-C, 6-TG, MTX, VCR, Adr, HHT six drugs. 51 cases of newly diagnosed non-leukemia patients (ANLL) cells in vitro susceptibility testing, 20 cases of both the results of in vivo treatment. In vitro and in vivo results show that the treatment of patients with sensitive drugs in vitro, 72.7% of clinical remission, of which 4 cases of two kinds of drugs at the same time sensitive in vitro, were relieved; only one drug in vitro sensitive. 4 of 7 cases were relieved. Nine patients in vitro treatment of all therapeutic drugs are not sensitive, eight patients do not relieve. Therefore, this group of patients in vitro susceptibility testing can be linked to clinical results, and prompts such as in vitro selection of one or more of the sensitive drug treatment, may significantly improve the treatment of leukemia remission rate.